Enovis Corp (ENOV)

Enovis Corp is trading at $21.59, up 3.75% on the session. The 50 day average sits at $20.88 and the 200 day at $23.37, which puts the stock in a downtrend. RSI is at 53.6, which reads as neutral, and MACD is bullish crossover. Volume is average.

The nearest support is around $17.30 with resistance near $27.46, so that band frames the current range. Average daily movement is roughly $0.92, or about 4.3% of the share price, which is what any stop placement has to allow for. The overall health score of 45 out of 100 combines a trend score of 20, momentum of 74 and a risk score of 46.

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.